Trials / Completed
CompletedNCT01305512
Pharmacokinetic, Safety and Tolerability Study of SPARC1028
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Sun Pharma Advanced Research Company Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of pharmacokinetic profile of SPARC1028
Detailed description
This is a phase I study of SPARC1028 and recommend phase II dose of SPARC1028 administered once a week for 3 weeks, followed by 1 week of rest.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SPARC1028 | SPARC1028 administration as 30-minute intravenous infusion once a week for 3 weeks, followed by 1 week of rest |
Timeline
- Start date
- 2012-05-01
- Primary completion
- 2016-06-01
- Completion
- 2016-08-01
- First posted
- 2011-02-28
- Last updated
- 2019-05-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01305512. Inclusion in this directory is not an endorsement.